Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Sunday's Bonus News Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks look overvalued by traditional measures, which can make it hard for investors to find candidates with the potential to double. Penny stocks (stocks trading below $5) often attract attention, but their risk-reward profile is usually appropriate only for nimble, highly risk-tolerant investors. There are still opportunities, though. One way to find them is to consider analyst sentiment. Analysts don't always get it right, but they often have access to company data and industry research that retail investors may not. Their views can be a useful input when doing due diligence on a stock. Trump's Next Export Ban Could Reshape the Global Economy
It's not semiconductors, AI chips or quantum computers. But none of those technologies can exist without it. On January 19th, 2026, Trump is expected to ban exports of something every tech company desperately needs—forcing them all to relocate to U.S. soil. See what he's about to ban here… With that in mind, here are three stocks trading under $50 per share that analysts see as having meaningful upside. While analysts aren't necessarily predicting doubles, consensus price targets are close enough that each could appreciate substantially if the economy and company fundamentals cooperate. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold mining company. As of Oct. 27, EQX is already up about 100% year-to-date. Still, analysts have a consensus price target of $26, implying upside of roughly 149% from current levels. Equinox is primarily a play on rising gold prices. Many analysts view mining stocks such as EQX as an efficient way for equity investors to capture gains from higher gold. The most bullish forecasts envision the spot price of gold reaching $5,000 before the end of 2025, with further gains possible in 2026. Higher spot prices improve Equinox's margins and profitability, while the key risk is that the gold rally could reverse. Institutional ownership of EQX is only about 38%, but it has climbed sharply over the past 12 months and has been trending higher for more than two years — a sign of growing institutional interest. Birkenstock: A Consumer Stock Ready to Rebound It's been a difficult year for consumer discretionary names like Birkenstock Group AG (NYSE: BIRK). BIRK is down about 25% in 2025, but the decline may reflect a general pullback in retail rather than company-specific weaknesses. Birkenstock's year-over-year revenue and earnings are higher, with double-digit revenue growth across segments and channels. Analysts project earnings growth of more than 26% over the next 12 months, which looks reasonable against a forward price-to-earnings (P/E) ratio near 23x. BIRK carries a short interest near 17%, which has declined over the last month. That could indicate short sellers are covering and also leaves some potential for a short squeeze if the stock rebounds sharply. Analysts have a consensus price target of $68.38 for BIRK, implying roughly 58% upside. The company reports third-quarter results on Dec. 17, and a strong holiday season could help lift the shares heading into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer treatments with T-cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or entering Phase 3 development. Biotech names are often singled out for their potential to double because a single successful drug launch can dramatically change a company's valuation. Immunocore is already generating measurable revenue and may be moving toward profitability. Analysts give IMCR a consensus price target of $61. More optimistic firms also see bigger upside: HC Wainwright reiterated its Buy rating on Oct. 22 and set a $100 price target. Not all analysts are bullish, though. Weiss Research assigns a Sell rating, reflecting the view that much of the company's growth may already be priced into the stock. None of these ideas is a guaranteed winner — market conditions and company execution matter. Investors should weigh analyst sentiment alongside fundamentals, risks, and their own investment horizons before making decisions.
| 
